Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy can cause vomiting. Clinical trial data show that nausea and vomiting are among the most commonly reported side effects of semaglutide 2.4mg, particularly during the first weeks of treatment and after each dose increase. For most people the symptoms are mild to moderate and ease within days. They don't mean the medicine isn't working — quite the opposite. The STEP 1 trial, published in the New England Journal of Medicine, recorded gastrointestinal side effects including nausea and vomiting in a substantial proportion of participants on semaglutide, with the majority settling as the body adjusted. These are prescription-only medicines, and a prescriber will assess whether Wegovy is appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial (68 weeks, 1,961 adults with obesity or overweight plus at least one weight-related condition) is the cornerstone evidence base for Wegovy at 2.4mg. Gastrointestinal events were the most frequently reported adverse effects across the semaglutide group. Nausea affected roughly 44% of participants; vomiting was reported by around 24%. Crucially, the large majority of these events were rated mild or moderate in intensity, and they clustered early: rates were highest in the weeks immediately after starting or after each step up in dose, then fell back as participants' bodies adapted to the medicine.
The NHS medicines page for semaglutide lists vomiting as a common side effect — meaning it affects more than one in every hundred people who take it. That classification doesn't mean everyone experiences it, and it doesn't mean those who do will feel unwell throughout their whole course of treatment. Many people find the worst of it passes within a fortnight of each dose change.
Why does it happen? Semaglutide activates GLP-1 receptors both in the gut and in the brain's appetite centres. One consequence is slower gastric emptying, food stays in the stomach longer, which reduces hunger effectively but can also tip into nausea or vomiting, especially if meals are large or fatty. Understanding the mechanism makes the pattern easier to predict and manage.
There's a meaningful difference between the expected settling-in response and a symptom that needs medical review. A prescriber at a service like nume's clinical team will go over this distinction with you, but the broad framework is straightforward.
Mild to moderate vomiting in the first one to two weeks after starting or after a dose increase (especially if it's improving day by day) sits within the documented adjustment pattern. It's uncomfortable, but it's not a signal that something has gone wrong. Keeping portions smaller, eating slowly, avoiding very fatty or rich meals, and staying well hydrated all help the body adapt. Some people find that taking a dose in the evening, so the peak effect falls during sleep, reduces how much nausea they notice.
Vomiting that is severe, that stops you keeping any fluids down, or that persists beyond two weeks without improving is a different matter. So is vomiting accompanied by intense abdominal pain that radiates toward the back, that combination warrants urgent medical attention, as the MHRA's Drug Safety Updates highlight acute pancreatitis as a known, though infrequent, serious risk associated with GLP-1 medicines. Signs of significant dehydration (very dark urine, dizziness on standing, no urge to urinate) also mean you should contact a clinician the same day rather than waiting.
If you're weighing up the full side-effect profile before starting, our Wegovy overview covers the broader picture alongside results evidence and eligibility criteria.
Wegovy's dosing ladder exists precisely because the GI side effects are predictable and dose-dependent. Treatment starts at 0.25mg weekly, a dose too low to produce meaningful weight loss on its own, but one that lets the gut, brain and stomach adjust to semaglutide's effects. Every four weeks or so, under prescriber guidance, the dose steps up through 0.5mg, 1.0mg, 1.7mg and finally 2.4mg. Staying at each level long enough before increasing is what keeps side effects manageable for most people.
If vomiting is significant at a particular dose, pausing the titration (staying at the current level for an extra month before moving up) is a legitimate clinical option. That decision sits with your prescriber, not with you alone. This is one reason aftercare access matters: being able to speak to a clinician when something feels wrong, rather than waiting weeks for a callback, makes a real practical difference. If you're in mid-treatment and struggling, our support team is available seven days a week.
It's also worth knowing that the newer 7.2mg Wegovy dose, approved by the MHRA in April 2026 for adults with a BMI of 30 or above, follows the same graduated starting schedule, the titration principle doesn't change just because the eventual maintenance dose is higher. If you've seen Wegovy ads and want to know whether the experience they depict matches the clinical reality, that page looks at what the campaigns show and what the evidence actually says. The question of what's normal when you're throwing up on Wegovy comes up often enough that we've covered it in more detail separately.
A handful of evidence-informed habits make a consistent difference. Eating smaller portions, chewing slowly, and stopping before feeling full work with the medicine's appetite-suppression rather than against it. Very rich, fatty foods are harder to process when gastric emptying is slowed, so dialling those back in the early weeks is sensible. Keeping up fluid intake matters, the risk of dehydration compounds quickly if vomiting is frequent.
Some people find that planning the injection for a quiet evening helps. By the next morning, the sharpest effects have often passed before the day begins, useful if you're managing a busy schedule or need to be functional first thing. That said, if you've found yourself wondering Wegovy made me throw up, so what do I do now, our dedicated page walks through the practical steps and when to seek clinical advice. The right injection timing for you is a conversation to have with your prescriber rather than a self-directed experiment.
For people exploring whether Wegovy is the right choice compared with other licensed options, our semaglutide information page and the treatment overview set out the differences clearly. If you'd like to understand what private Wegovy treatment costs and what that includes, the Wegovy price page has a plain breakdown. When you're ready to talk to a prescriber about whether this medicine is right for you, a free consultation with our clinical team is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.